

## COVID-19 antibodies – final products have new names

We have now started to launch our COVID-19 antibodies in their final forms. This means replacing clones we have produced *in vivo* with the corresponding clones produced *in vitro*. To separate the two production technologies from one another, we have determined different clone names for the *in vivo* and *in vitro* produced clones. If you have previously ordered any of the *in vivo* products, in the table below you can find the name for the corresponding product produced *in vitro*.

Similarly, we will launch some clones that until now have been available only as R&D samples. The clone name of the commercial product also will change according to the table below.

Note that we will update this list once we launch new clones.

<b>FINAL PRODUCT NAME AND FORMAT</b> <i>In vitro</i> or Recombinant commercial product	<b>PRODUCT REPLACED</b> <i>In vivo</i> or R&D sample
Cat.# 3CV4 Monoclonal anti-SARS-CoV-2 Nucleoprotein	
C518 ( <i>in vitro</i> )	NP1518 ( <i>in vivo</i> )
C525 ( <i>in vitro</i> )	NP1525 ( <i>in vivo</i> )
C706 (recombinant rabbit MAb)	NP3706 (R&D sample)
C715 (recombinant rabbit MAb)	NP3715 (R&D sample)
Cat.# 3CV2 Monoclonal anti-SARS-CoV-2 Spike	
R107 ( <i>in vitro</i> )	RBD1107 ( <i>in vivo</i> )

